Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

Elevated lipoprotein (a) [Lp(a)] levels increase the risk for CVD. Novel treatments that decrease LDL cholesterol (LDL-C) have also shown promise for reducing Lp(a) levels. Mipomersen, an antisense oligonucleotide that inhibits apoB synthesis, is approved for the treatment of homozygous familial hyp...

詳細記述

保存先:
書誌詳細
出版年:J Lipid Res
主要な著者: Nandakumar, Renu, Matveyenko, Anastasiya, Thomas, Tiffany, Pavlyha, Marianna, Ngai, Colleen, Holleran, Stephen, Ramakrishnan, Rajasekhar, Ginsberg, Henry N., Karmally, Wahida, Marcovina, Santica M., Reyes-Soffer, Gissette
フォーマット: Artigo
言語:Inglês
出版事項: The American Society for Biochemistry and Molecular Biology 2018
主題:
Patient-Oriented and Epidemiological Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6277161/
https://ncbi.nlm.nih.gov/pubmed/30293969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P082834
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料